These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 23734882)
1. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure. Mayer-Sonnenfeld T; Har-Noy M; Lillehei KO; Graner MW Int J Hyperthermia; 2013 Sep; 29(6):520-7. PubMed ID: 23734882 [TBL] [Abstract][Full Text] [Related]
2. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Graner MW; Romanoski A; Katsanis E Int J Hyperthermia; 2013 Aug; 29(5):380-9. PubMed ID: 23725202 [TBL] [Abstract][Full Text] [Related]
3. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582 [TBL] [Abstract][Full Text] [Related]
4. Chaperone-rich cell lysates, immune activation and tumor vaccination. Zeng Y; Graner MW; Katsanis E Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013 [TBL] [Abstract][Full Text] [Related]
5. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. Kislin KL; Marron MT; Li G; Graner MW; Katsanis E FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358 [TBL] [Abstract][Full Text] [Related]
6. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Graner MW; Zeng Y; Feng H; Katsanis E Cancer Immunol Immunother; 2003 Apr; 52(4):226-34. PubMed ID: 12669247 [TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines. Graner MW; Lillehei KO; Katsanis E Front Oncol; 2014; 4():379. PubMed ID: 25610811 [TBL] [Abstract][Full Text] [Related]
8. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Epple LM; Bemis LT; Cavanaugh RP; Skope A; Mayer-Sonnenfeld T; Frank C; Olver CS; Lencioni AM; Dusto NL; Tal A; Har-Noy M; Lillehei KO; Katsanis E; Graner MW Int J Hyperthermia; 2013 Aug; 29(5):390-8. PubMed ID: 23786302 [TBL] [Abstract][Full Text] [Related]
9. Intracellular and extracellular Hsp70 chaperone as a target for cancer therapy. Guzhova IV; Shevtsov MA; Abkin SV; Pankratova KM; Margulis BA Int J Hyperthermia; 2013 Aug; 29(5):399-408. PubMed ID: 23845032 [TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Luk JM; Lam CT; Siu AF; Lam BY; Ng IO; Hu MY; Che CM; Fan ST Proteomics; 2006 Feb; 6(3):1049-57. PubMed ID: 16400691 [TBL] [Abstract][Full Text] [Related]
12. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Li G; Andreansky S; Helguera G; Sepassi M; Janikashvili N; Cantrell J; Lacasse CL; Larmonier N; Penichet ML; Katsanis E Mol Cancer Ther; 2008 Mar; 7(3):721-9. PubMed ID: 18347157 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988 [TBL] [Abstract][Full Text] [Related]
14. Characterization of polyvalent allogeneic vaccines. Van Epps D Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185 [TBL] [Abstract][Full Text] [Related]
15. Cancer vaccination. Del Vecchio M; Parmiani G Forum (Genova); 1999; 9(3):239-56. PubMed ID: 10504171 [TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of human retinal and choroidal endothelial cells reveals molecular heterogeneity related to tissue of origin. Zamora DO; Riviere M; Choi D; Pan Y; Planck SR; Rosenbaum JT; David LL; Smith JR Mol Vis; 2007 Oct; 13():2058-65. PubMed ID: 18079679 [TBL] [Abstract][Full Text] [Related]
18. Genetically modified tumour vaccines--where we are today. Nawrocki S; Mackiewicz A Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic cancer vaccines: using unique antigens. Lewis JJ Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14653-6. PubMed ID: 15297620 [TBL] [Abstract][Full Text] [Related]
20. High throughput proteomic strategies for identifying tumour-associated antigens. Gunawardana CG; Diamandis EP Cancer Lett; 2007 Apr; 249(1):110-9. PubMed ID: 17306453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]